The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

Similar documents
Differential diagnosis of HCC

DOUBLE STAINS. Toll-Free: Direct:

CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY

New Developments in Immunohistochemistry for Gynecologic Pathology

Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

Single and Multiplex Immunohistochemistry

Carcinoma of unknown primary origin (CUP) is defined

8 years later! Next Generation Sequencing. Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_ ) (VAF: 59%) HNF1A Loss

Carcinoma of Unknown Primary (CUP)

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix

NEW IHC A n t i b o d i e s

Liver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle

The clinically challenging entity of liver metastasis from tumors of unknown primary

Histopathological diagnosis of CUP

Technology from Abcam

Nordic Immunohistochemical Quality Control

Reporting of carcinoma of unknown primary tumour (CUP)

A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Pathology Mystery and Surprise

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources

Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:

THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB

CODING TUMOUR MORPHOLOGY. Otto Visser

Pitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD

Speaking to you. This statement by Dr. Rodney T. Miller, Director of

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

C.L. Davis Foundation Descriptive Veterinary Pathology Course

What I Learned from 3 Cases and 3 Antibodies

Renal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford

Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases

Diagnostic IHC in lung and pleura pathology

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba

Disclosure of Relevant Financial Relationships

Outline. Hepatocellular Carcinoma Histologic variants. HCC: Histologic variants

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016

List of Available TMAs in the PRN

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

I. Diagnosis of the cancer type in CUP

Video Microscopy Tutorial 8

IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors

Case 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:

Malignant neoplasms of the gastrointestinal (GI) tract,

Immunohistochemical Evaluation of Necrotic Malignant Melanomas

Case Hx. Mrs. CP 69 female non smoker Presented with 20 lb weight loss Some changes in bowel habit but no bleeding Upper abdominal discomfort PMH

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Immunoexpression of napsin a in renal neoplasms

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Unknown Slides Conference

Pancreatic Cytopathology: The Solid Neoplasms

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma?

Effusion Cytology: Diagnostic Challenges

Serous effusion Objectives. Cytology of Serous Effusions From basics to challenges

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?

Immunohistochemistry on Fluid Specimens: Technical Considerations

FINALIZED SEER SINQ QUESTIONS January June, 2016

My personal experience at University of Toronto and recent updates of

4/17/2015. Case 1. A 37 year old man with a 2.2 cm solitary left thyroid mass.

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases

Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review

Update on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center

Intrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays

FINALIZED SEER SINQ QUESTIONS

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Prostate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships

Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1

Case 4 Diagnosis 2/21/2011 TGB

DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES

BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES

PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

IHC Panels as an Aid in Diagnostic Decision Making

Adenocarcinoma of the Cervix

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Neoplasms of the Canine, Feline and Lemur Liver:

The PAX8 gene is a member of the paired-box family of

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.

TUMOR M ARKERS MARKERS

Oncocytic-Appearing Salivary Gland Tumors. Oncocytic, Cystic, Mucinous, and High Grade Salivary Gland Tumors SALIVARY GLAND FNA: PART II

ISSN X (Print) Original Research Article. DOI: /sjams

Basement membrane in lobule.

CASE year old male with a PET avid nodule in the left adrenal gland

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Impact of immunostaining of pulmonary and mediastinal cytology

RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS?

Transcription:

The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation

Cell Marque Rocklin, California

About Cell Marque: IVD primary antibody manufacturer Distributors in 50+ countries 60+ Employees 2 pathologists on Staff Staff of primarily Biologists All employees trained on the science of IHC Focus on education, and increasing the diagnostic power of the pathologist

What is immunohistochemistry? Immuno Immunology: branch of science dealing with the immune system Histo Histology: branch of biology dealing with the study of organic tissues Chemistry The science of the composition, structure, properties and reactions of matter

Definition of Immunohistochemistry: Using a microscope to localize specific antigens in tissues by staining them with antibodies labeled with pigmented material.

Allows for visualization of proteins under a microscope Provides a diagnostic and prognostic tool for pathologists Detects infectious agents Importance of IHC

What is an antibody? Antibodies are proteins used by the immune system to identify and neutralize foreign objects.

Antibody Structure

Antigens Antigen: a molecule that stimulates an immune response Epitope: three dimensional surface features found on an antigen molecule Antigen Cell Membrane/Nucleus/Cytoplasm

What is a Panel? Panels are diagnostic algorithms used to immunophenotype specific types of tumors and neoplasms.

Grids Flow Chart Immmunophenotype Panel Types GCDFP15+ Mammaglobin+ E-Cadherin - P120 Catenin - GCDFP-15+/ Mammaglobin+ E-Cadherin and p120 catenin E-cadherin+/ p120 catenin- E-cadherin+/ p120 catenin+ E-cadherin-/ p120 catenin+ Breast Lesion GCDFP-15 Mammaglobin B-catenin E-Cadherin CK, 34betaE12 p120 Lobular + + - - + + (cytoplasmic) Ductal + + + (membranous) + - + (membranous)

Undifferentiated Tumor Panel??????

Novel Markers: Completing the Panel

PAX-8 Pax 8 on ovarian ca Clone: MRQ-50 Visualization: Nuclear Ovarian Carcinoma (high sensitivity for serous ca) Thyroid transcription factor Kidney metastasis sensitivity over 85% Multiple applications USCAP 2010, IAP 2010

Thyroglobulin Calcitonin CK 19 Galectin-3 TTF-1 HBME-1 PAX 8 Thyroid Carcinomas Papillary Carcinoma + - + + + + + Follicular Carcinoma Medullary Carcinoma + - - - + - + - + + - + + + Benign Thyroid + - - - + - +

Ovarian Carcinoma PAX8 WT1 CA-125 CEA Ovarian CA, Serous + + + + Ovarian CA, Mucinous - - - - Ovarian endometrioid CA + - + - Ovarian Clear Cell Carcinoma + - + -

RCC CD10 PAX-2 PAX-8 Ksp- Cadherin Ep-CAM Caveolin-1 Kidney Clear cell + + + + - - - Chromophobe - - - + + + + Oncocytoma - - - + + - -

Napsin A Clone: Polyclonal Visualization: Cytoplasmic Lung adenocarcinoma Multiple panel applications Higher sensitivity and specificity compared to TTF-1 USCAP 2010, IAP 2010

SOX-2 SOX-2 on Lung Squamous Cell Carcinoma Clone: SP76 Visualization: Nuclear Rabbit Monoclonal Differentiates lung squamous cell carcinoma from lung adenocarcinoma Distinguishes embryonal carcinoma from other germ cell tumors Useful in the identification of astrocytomas Important for general pathologists and GU pathologists

Lung Adenocarcinoma vs. Squamous Cell Carcinoma Napsin A + Napsin A + Napsin A - Napsin A - TTF-1 + TTF-1 - TTF-1 + TTF-1 - CK 5/14 - CK 5/14 - CK 5/14 - CK 5/14 + Sox-2 - Sox-2 - Sox-2 -/+ Sox-2 + Well Differentiated Lung Adenocarcinoma Poorly Differentiated Lung Adenocarcinoma Neuroendocrine Tumor (verify w/ne marker) Squamous Cell Carcinoma

Arginase-1 Arginase 1 on cirrhotic liver Clone: SP156 Visualization: cytoplasmic and nuclear High sensitivity for HCC Useful for HCC but also stains hepatic adenoma and cirrhotic liver Used in combination with Glypican 3 and HepPar-1 to distinguish benign from malignant

Glypican-3 Glypican-3 on HCC Clone: 1G12 Visualization: Cytoplasmic Differentiates benign liver from hepatocellular ca Also useful in identifying choriocarcinoma and yolk sac tumor Benign vs. malignant marker Unique to Cell Marque

Liver Neoplasms Arginase-1 Hep Par-1 Glypican-3 CD10 pcea Hepatic Adenoma + + - + + Hepatocellular Carcinoma Metastatic Adenocarcinoma + + + + + - - - -/+ -/+

Sox-11 Sox-11 on Mantle Cell Lymphoma Clone: MRQ-58 Visualization: Nuclear Positive in 93-100% of all cyclin D1+ Mantle Cell Lymphomas and 100% of cyclin D1- MCL Also useful in defining pathological features of CD5+DLBCL(-) Stains Burkitt s and Lymphoblastic lymphoma that cyclin D1 does not

Hematolymphoid Neoplasm Sox-11 CD20 CD5 CD10 CD23 Cyclin D1 MCL + + + - - + FL - + - + - - SLL/CLL - + + - + - MZL - + - - - - LBL + + - +/- - - BL -/+ + - - - - CD5+ DLBCL - + + + - - Blastoid Variant MCL + + + - - +

E-Cadherin/p120 Catenin Dual Stain E-cadherin-DAB, p120 catenin-red

Breast Carcinoma GCDFP-15+/ Mammaglobin+ E-Cadherin and p120 catenin E-Cadherin+/ p120 catenin- E-Cadherin+/ p120 catenin+ E-Cadherin-/ p120 catenin+ Ductal breast carcinoma Tubulolobular breast carcinoma Lobular breast carcinoma

SOX-10 SOX-10 on Melanoma Clone: Polyclonal Visualization: Nuclear Sensitive marker for melanoma (including conventional, spindle cell and desmoplastic subtypes) Superior to other immunostains in detecting residual invasive and in situ melanoma Useful in detecting in situ and invasive components of desmoplastic melanoma Antibody unique to CM

Cutaneous Lesion SOX-10 CK Cocktail HMB-45 S-100 MART-1 (Melan A) Conventional Melanoma Desmoplastic Melanoma Squamous Cell Carcinoma Basal Cell Carcinoma Merkel Cell Carcinoma + -/+ + + + + - - +/- - - + - -/+ - - + - - - - -/+ - -/+ -

Why are panels important? Increase the number of diagnostic tools for the pathologists See a macroview of the disease state Faster turn around time No single antibody is 100% sensitive and specific More specific diagnosis leads to more specific treatment

Questions?